An in vitro and in vivo preclinical study showed that pharmacological inhibition of KDM5 via KDM5-Inh1 developed by Gilead Sciences results in antitumor effects in HER2+ BC cell lines97. The gene discussed is ERBB2; the disease is breast cancer.